基于患者报告结局评估(PROBE)的炎症性肠病患者生活质量新型评价工具
利用IBD Partners队列对4854例患者(64%克罗恩病、36%溃疡性结肠炎)进行横断面与纵向分析,创建并验证了含6个条目的PROBE生活质量量表。PROBE在疾病活动期患者中随访评分较基线显著下降,Cronbach α在克罗恩病为0.87、溃疡性结肠炎为0.82,与短版炎症性肠病问卷相关性好。
要点
- PROBE为6条目患者报告结局量表,用于评估炎症性肠病心理社会负担。
- 克罗恩病与溃疡性结肠炎患者发作时PROBE评分较基线显著下降。
- PROBE与短版炎症性肠病问卷相关性好(克罗恩病r=0.88,溃疡性结肠炎r=0.86)。
核心结论
- 使用公开可用的调查条目创建了一种评估炎症性肠病患者生活质量的新量表PROBE,可用于临床诊疗、临床与流行病学研究及质量改进。
研究设计与样本
- 利用克罗恩病与结肠炎基金会IBD Partners队列,进行多项横断面与纵向分析,创建并验证PROBE。
- 采用因子分析和Pearson相关检验筛选候选条目,用Wilcoxon秩和检验评估PROBE对疾病活动变化的反应性,并在疾病活动稳定的患者中评估重测信度。
- 将PROBE与短版炎症性肠病问卷比较以评估结构效度。
主要发现
- 共4854例患者(64%克罗恩病,36%溃疡性结肠炎)完成调查,最终PROBE包含6个条目。
- 与基线相比,随访时发生发作的溃疡性结肠炎患者PROBE评分显著下降(25.0 vs 22.2,P=0.001)。
- 与基线相比,随访时发生发作的克罗恩病患者PROBE评分显著下降(23.1 vs 21.0,P<0.001)。
- 疾病活动稳定的患者中,Cronbach α在克罗恩病为0.87、溃疡性结肠炎为0.82。
- PROBE与短版炎症性肠病问卷相关性好:克罗恩病r=0.88,溃疡性结肠炎r=0.86。
临床怎么用
- 原文结论认为该PROBE可用于促进临床诊疗、临床与流行病学研究及质量改进。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: There is increased interest in measuring patient-reported outcomes (PROs) such as quality of life (QoL) among patients with inflammatory bowel disease (IBD). We aimed to create and validate a new measure of QoL to assess the psychosocial burden of IBD using publicly available assessment tools. METHODS: Using the Crohn's & Colitis Foundation's IBD Partners cohort, we performed several cross-sectional and longitudinal analyses to create a new PRO-based evaluation (PROBE) of QoL among patients with Crohn's disease (CD) and ulcerative colitis (UC). We used factor analysis and Pearson correlation test to identify candidate questions for inclusion, Wilcoxon rank-sum test to examine responsiveness of the PROBE to changes in disease activity, and test-retest reliability assessments in patients with stable disease activity. We also compared the PROBE to the Short Inflammatory Bowel Disease Questionnaire to assess construct validity. RESULTS: A total of 4,854 patients (64% CD, 36% UC) completed surveys with 6 items included in the final PROBE. Compared with baseline there was a significant decrease in PROBE scores at follow-up among patients who experienced a flare for UC (25.0 vs 22.2, P = 0.001) and CD (23.1 vs 21.0, P < 0.001). Among patients with stable disease activity, Cronbach alpha was 0.87 in CD and 0.82 in UC. The PROBE correlated well with the Short Inflammatory Bowel Disease Questionnaire in CD (r = 0.88) and UC (r = 0.86). DISCUSSION: We created a novel measure to assess QoL in patients with IBD using publicly available survey items. This new PROBE can be used to facilitate clinical care, clinical and epidemiological research, and quality improvement.
引用
- Barnes EL, Kappelman MD, Long MD, et al. A Novel Patient-Reported Outcome-Based Evaluation (PROBE) of Quality of Life in Patients With Inflammatory Bowel Disease. Am J Gastroenterol. 2019. PMID: 30848727. doi:10.14309/ajg.0000000000000177
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。